[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201000097A1 - 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов - Google Patents

8-бета-замещенные эстратриены в качестве селективно активных эстрогенов

Info

Publication number
EA201000097A1
EA201000097A1 EA201000097A EA201000097A EA201000097A1 EA 201000097 A1 EA201000097 A1 EA 201000097A1 EA 201000097 A EA201000097 A EA 201000097A EA 201000097 A EA201000097 A EA 201000097A EA 201000097 A1 EA201000097 A1 EA 201000097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
strogen
beta
selective active
estrogen receptor
uterus
Prior art date
Application number
EA201000097A
Other languages
English (en)
Other versions
EA017124B1 (ru
Inventor
Олаф Петерс
Нико Брэюр
Ина Тиме
Катя Прелле
Ханс-Петер Мун
Карл-Генрих Фритцемайер
Original Assignee
Байер Шеринг Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Шеринг Фарма Акциенгезельшафт filed Critical Байер Шеринг Фарма Акциенгезельшафт
Publication of EA201000097A1 publication Critical patent/EA201000097A1/ru
Publication of EA017124B1 publication Critical patent/EA017124B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к производным 8β-замещенного эстра-1,3,5(10)-триена общей формулы (I)их применению в качестве фармацевтически активных ингредиентов, которые обладают ii vitro более высокой аффинностью по отношению к препаратам эстрогенного рецептора из предстательной железы крыс, чем к препаратам эстрогенного рецептора из матки крыс, а также предпочтительным действием in vivo в яичнике по сравнению с маткой, их получению, их терапевтическому применению и к фармацевтическим дозированным формам, которые содержат такие новые соединения.
EA201000097A 2007-07-12 2008-07-11 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов EA017124B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07075600A EP2014672A1 (en) 2007-07-12 2007-07-12 8-beta-substituted estratrienes as selectively active estrogens
PCT/EP2008/059115 WO2009007454A2 (en) 2007-07-12 2008-07-11 8-beta-substituted estratrienes as selectively active estrogens

Publications (2)

Publication Number Publication Date
EA201000097A1 true EA201000097A1 (ru) 2010-08-30
EA017124B1 EA017124B1 (ru) 2012-10-30

Family

ID=38657613

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000097A EA017124B1 (ru) 2007-07-12 2008-07-11 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов

Country Status (34)

Country Link
US (1) US20090029957A1 (ru)
EP (2) EP2014672A1 (ru)
JP (1) JP2010533152A (ru)
KR (1) KR20100037593A (ru)
CN (1) CN101687902B (ru)
AR (1) AR067507A1 (ru)
AU (1) AU2008274198A1 (ru)
BR (1) BRPI0814207A2 (ru)
CA (1) CA2692727A1 (ru)
CL (1) CL2008002027A1 (ru)
CO (1) CO6270230A2 (ru)
CR (1) CR11211A (ru)
CU (1) CU23885B1 (ru)
CY (1) CY1113351T1 (ru)
DK (1) DK2176282T3 (ru)
DO (1) DOP2010000017A (ru)
EA (1) EA017124B1 (ru)
EC (1) ECSP109872A (ru)
ES (1) ES2393942T3 (ru)
HN (1) HN2010000081A (ru)
HR (1) HRP20120952T1 (ru)
MA (1) MA31565B1 (ru)
NZ (1) NZ582490A (ru)
PA (1) PA8789401A1 (ru)
PE (1) PE20090825A1 (ru)
PL (1) PL2176282T3 (ru)
PT (1) PT2176282E (ru)
RS (1) RS52541B (ru)
SI (1) SI2176282T1 (ru)
TN (1) TN2010000007A1 (ru)
TW (1) TW200911824A (ru)
UA (1) UA99918C2 (ru)
UY (1) UY31220A1 (ru)
WO (1) WO2009007454A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508784A (ja) * 2011-03-25 2014-04-10 ユニヴェルシテ ラヴァル １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤
CA3028990C (en) * 2016-06-24 2024-04-09 K&N Engineering, Inc. Compound air filters and methods thereof
USD905747S1 (en) 2018-04-09 2020-12-22 Mitsubishi Electric Corporation Display screen with animated graphical user interface

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
JP3828423B2 (ja) * 2000-04-12 2006-10-04 シエーリング アクチエンゲゼルシャフト ８β−置換された１１β−ペンチル−及び１１β−ヘキシル−エストラ−１，３，５（１０）−トリエン誘導体類

Also Published As

Publication number Publication date
CR11211A (es) 2010-04-27
DOP2010000017A (es) 2010-01-31
CO6270230A2 (es) 2011-04-20
CL2008002027A1 (es) 2009-01-16
US20090029957A1 (en) 2009-01-29
UY31220A1 (es) 2009-03-02
CN101687902A (zh) 2010-03-31
PT2176282E (pt) 2012-11-30
CU20100008A7 (es) 2011-05-27
PE20090825A1 (es) 2009-07-25
WO2009007454A2 (en) 2009-01-15
AR067507A1 (es) 2009-10-14
JP2010533152A (ja) 2010-10-21
CY1113351T1 (el) 2016-06-22
SI2176282T1 (sl) 2013-02-28
DK2176282T3 (da) 2012-12-03
KR20100037593A (ko) 2010-04-09
TN2010000007A1 (en) 2011-09-26
EP2176282B1 (en) 2012-08-22
TW200911824A (en) 2009-03-16
HRP20120952T1 (hr) 2012-12-31
UA99918C2 (ru) 2012-10-25
ES2393942T3 (es) 2013-01-02
CN101687902B (zh) 2013-07-24
EP2176282A2 (en) 2010-04-21
HN2010000081A (es) 2013-07-01
PL2176282T3 (pl) 2013-06-28
BRPI0814207A2 (pt) 2015-01-27
PA8789401A1 (es) 2009-04-23
AU2008274198A1 (en) 2009-01-15
CA2692727A1 (en) 2009-01-15
NZ582490A (en) 2012-03-30
MA31565B1 (fr) 2010-08-02
EA017124B1 (ru) 2012-10-30
ECSP109872A (es) 2010-02-26
EP2014672A1 (en) 2009-01-14
CU23885B1 (es) 2013-04-19
WO2009007454A3 (en) 2009-03-05
RS52541B (en) 2013-04-30

Similar Documents

Publication Publication Date Title
DK1272505T3 (da) 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater
RU2007101304A (ru) Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение
CO6660506A2 (es) Derivados de 6.7-dihidro -5h-benzon [7]anulenos, métodos para su preparación, preparaciones farmaceúticas que los contiene y su uso para la preparación de medicamentos
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
ES2299730T3 (es) Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
EA200100828A1 (ru) 16-гидроксиэстратриены в качестве эстрогенов избирательного действия
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
EA200702604A1 (ru) Производные бензофуранона как нестероидные модуляторы рецептора прогестерона
ES2286042T3 (es) 18-nor-esteroides como estrogenos eficaces selectivamente.
RS107004A (en) 9-alpha-substituted estratrienes as selectively active estrogen
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
UY28910A1 (es) Prodrogas de estriol y estetrol
AR033260A1 (es) Nueva composicion hormonal y su utilizacion
TH114620A (th) 8-บีตา-ซับสทิทิวเทด เอสทราไทรอีนที่เป็นเอสโทรเจนที่ออกฤทธิ์อย่างมีอำนาจเลือก
UY26967A1 (es) Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.-

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU